Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Video Conference Visits Effective in Reducing Stress, Anxiety in Caregivers for Patients with Cancer
May 14th 2020The use of video conference technology significantly reduced anxiety and stress among individuals who provide care for an individual with cancer and live more than one hour away from the patient.
Integrated Geriatric Assessment Optimizes Care for Older Adults with Cancer
May 13th 2020Integration of a comprehensive geriatric assessment with geriatrician-led management care improved health-related quality of life, unplanned hospital admissions, and treatment discontinuation among older adults undergoing systemic therapy for their cancer.
Maintenance Therapy with Olaparib Extends Survival in Relapsed, BRCA+ Ovarian Cancer
May 13th 2020Treatment with olaparib in the maintenance setting extended overall survival by 12.9 months in women with platinum-sensitive relapsed ovarian cancer with BRCA1/2 mutations, compared with placebo, according to randomized phase 3 trial results presented during a 2020 ASCO Virtual Scientific Program press briefing.
COM701 Shows Early Promise as Monotherapy and Combined With Nivolumab in Advanced Solid Tumors
COM701, a novel, first-in-class immune checkpoint inhibitor, was found to demonstrate encouraging preliminary antitumor activity and good tolerability when used as either a monotherapy and in combination with nivolumab in a number of heavily pretreated patients with advanced or metastatic solid tumors, according to data from a phase 1 trial.
cfDNA Assay Shows Predictive Value in Detecting Cancer, Tissue of Origin
April 29th 2020A cell-free DNA test demonstrated the potential to detect cancer and predict tissue of origin in patients with a suspicion of cancer, according to findings from the Circulating Cell-free Genome Atlas study presented at the 2020 AACR Virtual Annual Meeting I.
TERAVOLT Data Reveal "Unexpectedly High" Mortality in Patients With Thoracic Cancers and COVID-19
Early data from TERAVOLT, a global registry collecting characteristics and outcomes of patients with thoracic cancers affected by COVID-19, suggested an unexpectedly high mortality among this patient population.
TIL Therapy Elicits Encouraging Activity in Advanced NSCLC
April 29th 2020Adoptive cell transfer with tumor-infiltrating lymphocytes was found to be feasible, have a manageable toxicity profile, and expanded in 95% of patients with metastatic non–small cell lung cancer who had disease progression on nivolumab (Opdivo).
Dr. Pusztai on Rationale for the I-SPY 2 Trial With Durvalumab/Olaparib Combo in HER2- Breast Cancer
April 29th 2020Lajos Pusztai, MD, DPhil, discusses the rationale for the phase 2 I-SPY 2 trial examining the addition of durvalumab and olaparib to neoadjuvant paclitaxel in HER2-negative breast cancer.
Positive Safety Profile Reported for Atezolizumab/Axi-Cel Combo in DLBCL
April 29th 2020A manageable safety profile was observed for the combination of atezolizumab and the anti-CD19 chimeric antigen receptor T-cell therapy, axicabtagene ciloleucel, in patients with refractory diffuse large B-cell lymphoma.
Universal Allogeneic CAR T-Cell Product Demonstrates Efficacy in a Cohort of Adult T-ALL
April 29th 2020The first-in-clinic universal CAR T-cell therapy TruUCAR GC027 induced promising early response rates and demonstrated a manageable safety profile with no evidence of neurotoxicity events or graft-versus-host disease in adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia.
Adopting Multidisciplinary and Evolving Care Plans Are Essential to Treat Cancer and COVID-19
Treating patients with cancer and coronavirus disease 2019 depends upon rapidly changing assessments of the standard of care as well as considerations of comorbidities and life expectancy.
Results of a Combined Modality Screening Approach in Women Without Cancer History
April 28th 2020Nickolas Papadopoulos, PhD, professor of oncology and pathology, Johns Hopkins University School of Medicine, discusses the results of a study which evaluated a combined modality screening approach in women without a history of cancer.
Dr. DiBiase on Data With DM-CHOC-PEN/Radiation in Cancers Involving the CNS
April 28th 2020Steven J. DiBiase, MD, chair and chief of service for the Julia and Ned Arnold Center for Radiation Oncology, NewYork-Presbyterian Queens, vice chairman and assistant interim professor of radiation oncology, Weill Cornell Medicine, discusses data with 4-demethyl-4 cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) plus radiation in cancers involving the central nervous system (CNS).
Novel Innate Immune Activator Boosts PD-1 Inhibition Responses in mTNBC
The addition of the novel innate immune activator, Imprime PGG, to checkpoint inhibition with pembrolizumab showed pronounced clinical benefit in patients with previously treated metastatic triple-negative breast cancer.
Capmatinib Shows Clinical Meaningful Activity and Intracranial Responses in MET Exon 14+ NSCLC
April 28th 2020Results from the GEOMETRY mono-1 study demonstrated antitumor efficacy of and deep and durable responses with capmatinib in 97 patients with advanced non–small cell lung cancer who harbor MET exon 14 mutations.
.jpg?fit=crop&auto=format)
